在一个印度东部的平静社区，三天的恐惧笼罩之下，居民们的生活因一只失控猴子的暴行而陷入混乱，纷纷为自身安全采取防御措施。    (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed.    China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval.    A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country.    Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category.    This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading.     At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly.    To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong.    The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions.    In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total.        (By Tang Yuxian)                    。

二 | 萨勒普尔，位于奥里萨邦的一隅，正经历着前所未有的恐慌，一只凶猛的猴只发起了一系列无差别攻击，致一人重伤入院，其余多人遭受重创，整个社区为之震动。

这只肆意妄为的猴子在连续三天的时间里，如同一名无法无天的游荡者，令六位无辜市民深受其害，其攻击行为之猛烈，让所有目击者胆寒。

三 | 当地新闻媒体详尽报道了这一系列骇人事件，描述这只噬人的野生动物如何在光天化日下逍遥法外，无所顾忌。

目前，市民们因极度恐惧而选择自我隔离于家中，不敢轻易踏出房门半步，唯恐成为下一个受害者。一名知情人士向卡林加电视台透露：“如今，出门已成奢侈，人人手持木棍自保，成了无奈的日常。我们迫切呼吁相关部门迅速采取行动，捕获这只猴子。

四 | ”

尽管有传言称政府部门正紧急策划围捕行动以应对这一特殊威胁，但具体实施细节及进展仍待官方证实。值得注意的是，萨勒普尔，这个坐落于奇特罗塔拉河畔的小镇，因其丰富的灵长类生态和错综复杂的洞穴网络而闻名遐迩，近年来频繁因猴群相关新闻登上头条。2020年，该地区因猴群相关事件再次受到关注，当时由于新冠疫情，旅游活动暂停，导致依赖游客投食的猴群面临饥饿危机，生存状况堪忧。

彼时，一位代表曾解释：“这些猴子习以为常地依赖于游客提供的食物。疫情封锁切断了食物来源，它们只能无助地守在人们家门口，期盼有人施舍。它们已适应了这样的生活方式，无处可去。它们通常极为友善，对人类并不构成威胁。”

然而，讽刺的是，当前一只猴子的独行暴行似乎在独自挑战这一长期建立的无害形象，它的行动无疑给社区蒙上了一层阴影，也引发了关于人与自然平衡的新一轮思考。